The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase III trial of adjuvant neratinib (NER) after trastuzumab (TRAS) in women with early-stage HER2+ breast cancer (BC).
P. E. Goss
Honoraria - Pfizer
Research Funding - Pfizer
C. H. Barrios
Consultant or Advisory Role - Pfizer
A. Chan
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche
S. K. L. Chia
Consultant or Advisory Role - Pfizer
S. Delaloge
Consultant or Advisory Role - Pfizer
Honoraria - Pfizer
B. Ejlertsen
Consultant or Advisory Role - Pfizer
J. N. Ingle
Consultant or Advisory Role - Pfizer
B. Moy
No relevant relationships to disclose
H. Iwata
No relevant relationships to disclose
F. A. Holmes
Consultant or Advisory Role - Philips Healthcare
Honoraria - Genentech; Novartis
J. Mansi
Consultant or Advisory Role - Pfizer
Research Funding - Pfizer
G. Von Minckwitz
Research Funding - Pfizer
L. Han
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
A. Thiele
Employment or Leadership Position - Pfizer
V. Agrapart
Employment or Leadership Position - Pfizer
A. Freyman
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
J. Truscello
Employment or Leadership Position - Pfizer
A. Berkenblit
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
D. Finkelstein
No relevant relationships to disclose